Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic Predictors of Outcome in Prostate Cancer.
Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR. Boström PJ, et al. Eur Urol. 2015 Dec;68(6):1033-44. doi: 10.1016/j.eururo.2015.04.008. Epub 2015 Apr 23. Eur Urol. 2015. PMID: 25913390 Free article. Review.
Nutraceuticals and prostate cancer prevention: a current review.
Trottier G, Boström PJ, Lawrentschuk N, Fleshner NE. Trottier G, et al. Among authors: bostrom pj. Nat Rev Urol. 2010 Jan;7(1):21-30. doi: 10.1038/nrurol.2009.234. Epub 2009 Dec 8. Nat Rev Urol. 2010. PMID: 19997071 Review.
A new and highly prognostic system to discern T1 bladder cancer substage.
van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, van der Aa MN, Kakiashvili DM, Bangma CH, Jewett MA, Zlotta AR. van Rhijn BW, et al. Among authors: bostrom pj. Eur Urol. 2012 Feb;61(2):378-84. doi: 10.1016/j.eururo.2011.10.026. Epub 2011 Oct 25. Eur Urol. 2012. PMID: 22036775
Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, Liukkonen T, Puolakka VM, Seppänen M, Tuhkanen K, Vaarala M, Viitanen J, Boström PJ; FinnBladder Group. Järvinen R, et al. Among authors: bostrom pj. Eur Urol. 2015 Oct;68(4):611-7. doi: 10.1016/j.eururo.2015.02.022. Epub 2015 Mar 5. Eur Urol. 2015. PMID: 25748117 Clinical Trial.
Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T, Järvinen R, Liukkonen T, Rintala E, Boström P, Seppänen M, Tammela T, Hellström P, Aaltomaa S, Leskinen M, Raitanen M, Kaasinen E; FinnBladder Group. Marttila T, et al. Eur Urol. 2016 Aug;70(2):341-7. doi: 10.1016/j.eururo.2016.03.034. Epub 2016 Apr 13. Eur Urol. 2016. PMID: 27085624 Clinical Trial.
183 results